William Hurtado-Santiago, MD
Nephrology · Mayaguez, PRNPI 1912022310
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $158,052 of the $190,609 with a category attached, or 82.9%. 30 manufacturers reported payments, led by AstraZeneca at 44.7% of the total. Among nephrology clinicians in PR with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 402 payments — averaging $474.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$85K
- Calliditas Therapeutics US Inc.$40K
- Boehringer Ingelheim$28K
- Lilly USA, LLC$24K
- Bayer$6K
- Johnson & Johnson$3K
- plus $5K from 24 others
Across 10 payments — averaging $5956.06 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$37K
- AstraZeneca$18K
- Vertex$4K
- Boehringer Ingelheim International GmbH$302
What the payments were for
- Consulting fees$2,0401%
- Speaking & faculty fees$158,05283%
- Travel & lodging$16,3789%
- Food & beverage$13,9267%
- Education$2140%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 147 | $85,241 |
| Calliditas Therapeutics US Inc. | 51 | $40,321 |
| Boehringer Ingelheim | 46 | $27,826 |
| Lilly USA, LLC | 28 | $23,675 |
| Bayer | 19 | $5,844 |
| Johnson & Johnson | 10 | $2,677 |
| Amgen(2 entities) | 15 | $870 |
| Medtronic | 14 | $771 |
| Nxstage Medical, Inc. | 5 | $527 |
| Travere Therapeutics, Inc. | 7 | $489 |
| ANI Pharmaceuticals, Inc. | 10 | $273 |
| Bard Access Systems, Inc. | 3 | $249 |
| Mallinckrodt Hospital Products Inc. | 4 | $188 |
| Novartis | 6 | $171 |
| Otsuka America Pharmaceutical, Inc. | 6 | $158 |
| Bayer Puerto Rico Inc. | 6 | $154 |
| Bard Peripheral Vascular, Inc. | 4 | $153 |
| E.r. Squibb & Sons, L.L.C. | 2 | $150 |
| BD | 6 | $127 |
| Apellis Pharmaceuticals, Inc. | 1 | $125 |
| Shionogi Inc | 1 | $123 |
| Perspectum Diagnostics Ltd | 1 | $117 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 1 | $104 |
| Boston Scientific | 3 | $103 |
| Kyowa Kirin, Inc. | 1 | $50 |
| GSK | 1 | $45 |
| Davol Inc. | 1 | $28 |
| Abbott | 1 | $22 |
| Mallinckrodt Enterprises LLC | 1 | $16 |
| Merck | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$190,609 in reported general payments places this provider in the 95th percentile of 161 nephrology providers in Puerto Rico.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| FarxigaDapagliflozin Propanediol | 880 | $590,534 |
| JardianceEmpagliflozin | 445 | $304,033 |
| TarpeyoBudesonide | 12 | $196,480 |
| KerendiaFinerenone | 178 | $127,603 |
| GlyxambiEmpagliflozin/Linagliptin | 123 | $82,062 |
| LokelmaSodium Zirconium Cyclosilicate | 63 | $53,542 |
| Trijardy XrEmpaglifloz/Linaglip/Metformin | 74 | $44,870 |
| Xigduo XrDapaglifloz Propaned/Metformin | 29 | $29,833 |
| OzempicSemaglutide | 17 | $18,693 |
| TrulicityDulaglutide | 15 | $14,752 |
| Sevelamer Carbonate | 119 | $13,277 |
| TradjentaLinagliptin | 19 | $11,075 |
| EliquisApixaban | 14 | $8,496 |
| XareltoRivaroxaban | 14 | $8,119 |
| Sodium Polystyrene Sulfonate | 60 | $7,259 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AstraZenecaFarxiga, Lokelma | $85,241 | $644,076943 claims |
| Boehringer IngelheimJardiance, Glyxambi, Trijardy Xr, Tradjenta | $27,826 | $442,040661 claims |
| Calliditas Therapeutics US Inc.Tarpeyo | $40,321 | $196,48012 claims |
| BayerKerendia | $5,844 | $127,603178 claims |
| Lilly USA, LLCTrulicity | $23,675 | $14,75215 claims |
| Johnson & JohnsonXarelto | $2,677 | $8,11914 claims |
| ANI Pharmaceuticals, Inc.Valsartan | $273 | $71240 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 161 nephrology providers in Puerto Rico.
Other nephrology in Mayaguez
- Jorge Weber AcevedoMayaguez$3K
- Eddie Rodriguez CastroToa Baja$591K
- William Vega OcasioCayey$40K
- Felix Perez RamosPonce$27K
- Antonio JimenezGuaynabo$16K
- Cesar Hernandez-ArroyoTrujillo Alto$13K
- Stephanie Colon-LopezBayamon$13K
- Pedro ColtonSanturce$12K
- Rafael Burgos CalderonBayamon$12K
- Angel Rivera SantosPonce$11K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.